Guaranteed Pass
60 Questions | 2026-2027 | 100% VERIFIED
Introduction
This comprehensive bank of 60 verified items evaluates the knowledge and clinical judgment
required for safe medication administration across the lifespan. Content is organized around the
eight domains of the official blueprint: Pharmacokinetics and Pharmacodynamics; Autonomic and
Central Nervous System Agents; Cardiovascular and Respiratory Medications; Antimicrobials and
Anti-infectives; Endocrine and Gastrointestinal Drugs; Analgesics, Anesthetics, and Psychotropics;
Chemotherapy and Immunological Agents; and Medication Administration, Safety, and Patient
Education. Every item presents four options, the verified correct answer, and a concise rationale
that explains the reasoning and why the remaining options are incorrect. Mastery of this material is
essential for professional certification and for confident, accurate clinical execution at the bedside,
where precise drug knowledge directly protects patient outcomes.
1. A nurse is evaluating a client's understanding of drug absorption. Which route delivers a
medication directly into the systemic circulation and bypasses the first-pass effect?
A. Oral tablet swallowed with water
B. Enteric-coated oral capsule
C. Intravenous bolus administration
D. Medication instilled through a nasogastric tube
Answer: C. Intravenous bolus administration
Rationale: Intravenous administration places the medication directly into the bloodstream,
bypassing hepatic first-pass metabolism and producing the highest bioavailability. Oral tablets,
enteric-coated capsules, and medications given through a nasogastric tube are absorbed
through the gastrointestinal tract, travel through the portal vein to the liver, and are partially
inactivated before reaching systemic circulation.
2. A client with cirrhosis and hypoalbuminemia is receiving a highly protein-bound medication. The
nurse should monitor the client for which effect?
A. Reduced therapeutic effect because more drug stays bound to protein
B. Increased risk for toxicity from a greater amount of free, unbound drug
C. Rapid renal excretion of the medication
D. No change in response because liver disease does not affect binding
Answer: B. Increased risk for toxicity from a greater amount of free, unbound drug
Rationale: Albumin is the major carrier protein for many drugs, so low albumin leaves more
unbound (free) drug available to produce effects and increases the risk for toxicity. Reduced
, protein binding does not lower therapeutic effect or speed renal excretion, and cirrhosis
clearly alters both protein binding and drug metabolism.
3. A client who takes warfarin is started on rifampin. Which laboratory finding should the nurse
anticipate?
A. Increased INR because rifampin inhibits warfarin metabolism
B. Decreased INR because rifampin induces hepatic enzymes that accelerate warfarin
metabolism
C. No change because rifampin does not interact with anticoagulants
D. Prolonged bleeding time while the INR remains unchanged
Answer: B. Decreased INR because rifampin induces hepatic enzymes that accelerate
warfarin metabolism
Rationale: Rifampin is a potent inducer of hepatic CYP450 enzymes, so it speeds warfarin
metabolism and lowers the INR, placing the client at risk for clotting. Rifampin does not inhibit
warfarin metabolism, it interacts significantly with anticoagulants, and a falling INR rather
than a prolonged bleeding time is the expected finding.
4. A medication has a half-life of 6 hours. Approximately how long will it take to reach a steady-state
serum level with a continuous dosing schedule?
A. 6 hours
B. 12 hours
C. 30 hours
D. 72 hours
Answer: C. 30 hours
Rationale: Steady-state serum levels are generally reached after approximately 4 to 5 half-
lives, so a drug with a 6-hour half-life reaches steady state in about 24 to 30 hours. Six hours is
one half-life, 12 hours is two half-lives, and 72 hours represents 12 half-lives, all of which
misstate the expected time frame.
5. Which prescribed medication requires the nurse to monitor serum drug levels because it has a
narrow therapeutic index?
A. Amoxicillin
B. Digoxin
C. Ibuprofen
D. Loratadine
Answer: B. Digoxin
Rationale: Digoxin has a narrow therapeutic index, so small changes in serum concentration
can cause bradycardia, nausea, and visual disturbances, making periodic level monitoring
essential. Amoxicillin, ibuprofen, and loratadine have wide margins of safety and do not
require routine serum level monitoring.
, 6. A client who received IV morphine develops a respiratory rate of 8/min and is difficult to arouse.
Which medication should the nurse anticipate administering?
A. Naloxone, an opioid antagonist
B. Flumazenil, a benzodiazepine antagonist
C. Additional morphine sulfate, an opioid agonist
D. Atropine, an anticholinergic agent
Answer: A. Naloxone, an opioid antagonist
Rationale: Naloxone is a competitive opioid antagonist that reverses morphine-induced
respiratory and central nervous system depression within minutes. Flumazenil reverses
benzodiazepines rather than opioids, more morphine would deepen the depression, and
atropine does not reverse opioid effects.
7. A client is prescribed a medication with a long half-life that requires a rapid therapeutic effect.
Which action should the nurse anticipate?
A. Doubling every scheduled dose for the first 24 hours
B. Withholding the drug until serum levels reach a steady state
C. Administration of a larger initial loading dose to reach therapeutic levels quickly
D. Administering the drug only when symptoms appear
Answer: C. Administration of a larger initial loading dose to reach therapeutic levels
quickly
Rationale: A loading dose is a larger initial amount given to reach therapeutic serum levels
quickly when a drug has a long half-life or a rapid response is needed. Doubling every dose
increases toxicity risk, withholding the drug delays therapy, and dosing only when symptoms
appear does not establish a therapeutic level.
8. A client who takes a medication metabolized by CYP3A4 reports drinking large amounts of
grapefruit juice daily. Which outcome is most likely?
A. Decreased drug levels because grapefruit juice speeds metabolism
B. Increased drug levels because grapefruit juice inhibits CYP3A4 metabolism
C. No effect, because grapefruit juice alters only cardiac medications
D. Reduced absorption because grapefruit juice binds the drug in the stomach
Answer: B. Increased drug levels because grapefruit juice inhibits CYP3A4 metabolism
Rationale: Grapefruit juice inhibits intestinal CYP3A4, which decreases first-pass metabolism
of susceptible drugs and raises serum levels and the risk for toxicity. It does not accelerate
metabolism, it is not limited to cardiac medications, and it does not bind drugs in the stomach
to reduce absorption.
9. A client is prescribed atropine. The nurse should monitor for which expected therapeutic effect?
A. Increased salivation and lacrimation
B. Pinpoint pupils with urinary urgency